Boothbay Fund Management’s Regeneron Pharmaceuticals REGN Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$2.07M Buy
3,312
+340
+11% +$231K 0.03% 706
2026
Q1
$2.3M Buy
+2,972
New +$2.28M 0.03% 560
2025
Q4
Sell
-4,240
Closed -$2.38M 2284
2025
Q3
$2.38M Buy
4,240
+1,541
+57% +$871K 0.03% 525
2025
Q2
$1.42M Buy
+2,699
New +$1.51M 0.03% 585
2025
Q1
Sell
-12,375
Closed -$8.82M 1713
2024
Q4
$8.82M Buy
12,375
+11,239
+989% +$9.43M 0.22% 123
2024
Q3
$1.19M Buy
+1,136
New +$1.26M 0.03% 699
2024
Q2
Sell
-5,081
Closed -$4.89M 1807
2024
Q1
$4.89M Buy
+5,081
New +$4.83M 0.09% 233
2023
Q3
Sell
-10,590
Closed -$7.61M 2014
2023
Q2
$7.61M Buy
10,590
+10,226
+2,809% +$7.88M 0.17% 119
2023
Q1
$299K Buy
364
+80
+28% +$60.3K 0.01% 1505
2022
Q4
$205K Buy
+284
New +$210K ﹤0.01% 1604
2020
Q3
Sell
-4,000
Closed -$2.5M 1188
2020
Q2
$2.5M Sell
4,000
-1,000
-20% -$568K 0.17% 154
2020
Q1
$2.44M Sell
5,000
-2,000
-29% -$825K 0.2% 127
2019
Q4
$2.63M Sell
7,000
-2
-0% -$673 0.23% 110
2019
Q3
$1.94M Buy
7,002
+887
+15% +$262K 0.18% 152
2019
Q2
$1.91M Buy
+6,115
New +$2.04M 0.17% 149

Other funds holding REGN

Boothbay Fund Management's REGN Position: Q2 2026 in Review

Boothbay Fund Management increased its Regeneron Pharmaceuticals (REGN) stake by 11% in Q2 2026, buying an estimated $231K and bringing the position to 3,312 shares worth $2.07M. The position accounts for 0.03% of the portfolio, ranked #706.

Boothbay Fund Management first reported a position in REGN in Q2 2019 and has held it in 15 quarters since. The position peaked at $8.82M in Q4 2024. 1,335 funds tracked by Wall St. Rank hold REGN as of Q2 2026.

  • Boothbay Fund Management held 3,312 shares of Regeneron Pharmaceuticals worth $2.07M as of Q2 2026.
  • Boothbay Fund Management bought 340 Regeneron Pharmaceuticals shares in Q2 2026, an estimated $231K.
  • Regeneron Pharmaceuticals made up 0.03% of Boothbay Fund Management's portfolio in Q2 2026, its #706 holding.
  • Boothbay Fund Management first reported a position in Regeneron Pharmaceuticals in Q2 2019 and has held it in 15 quarters since.
  • Boothbay Fund Management's Regeneron Pharmaceuticals position peaked at $8.82M in Q4 2024.
  • 1,335 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2026.

Based on Boothbay Fund Management's 13F filing for Q2 2026, filed 14 Aug 2026.